rivoglitazone
Small moleculeexperimental
Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00143520)
Timeline
Indications
Mechanism of action
PPARG agonist
Development discontinued in 2009, not sufficiently differentiate from existing product
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1- Mol. weight
- 397.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRivoglitazone ↗
- ChEMBLCHEMBL2104753 ↗
Also known as
- cs-011
- cs-011
- de-101
- de-101
- de-101
- r-106056
- r-106056
- rivoglitazone
- rivoglitazone
- rivoglitazone
- rivoglitazone
- rivoglitazone hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01468168 | Phase 2 | Oct 1, 2011 | Santen Inc. |
| NCT01118754 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2010 | Santen Inc. |
| NCT00571519 | Phase 3 | Nov 1, 2007 | Daiichi Sankyo |
| NCT00575874 | Phase 2 | Aug 1, 2007 | Daiichi Sankyo |
| NCT00575471 | Phase 2 | Jul 1, 2007 | Daiichi Sankyo |
| NCT00484198 | Phase 3 | Apr 1, 2007 | Daiichi Sankyo |
| NCT00143520 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2004 | Daiichi Sankyo |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 5 | 5 | 2 | 2004 |
| Santen Inc. | For profit | 2 | 2 | 1 | 2010 |
2 organizations
Page 1 / 1